Upsher-Smith launches generic Onfi
Upsher-Smith Laboratories is launching clobazam tablets 10 and 20 mg, and clobazam oral suspension 2.5 mg/mL.
Upsher-Smith’s clobazam products are the generic version of Lundbeck's Onfi (clobazam) tablets, and Onfi (clobazam) oral suspension.
Clobazam tablets had a market value of approximately $594 million for the 12 months ended August 2018, and the market value of clobazam oral suspension was approximately $255 million for the 12 months ended in August, according to IQVIA data.
“Upsher-Smith’s generic clobazam will provide patients and families with a generic alternative to Onfi,” Upsher-Smith president and CEO Rusty Field said in a statement. “The approval and launch of this product in both tablet and oral suspension forms offer yet another example of our commitment to growing and diversifying our generics portfolio.”
Upsher-Smith’s clobazam products are the generic version of Lundbeck's Onfi (clobazam) tablets, and Onfi (clobazam) oral suspension.
Clobazam tablets had a market value of approximately $594 million for the 12 months ended August 2018, and the market value of clobazam oral suspension was approximately $255 million for the 12 months ended in August, according to IQVIA data.
“Upsher-Smith’s generic clobazam will provide patients and families with a generic alternative to Onfi,” Upsher-Smith president and CEO Rusty Field said in a statement. “The approval and launch of this product in both tablet and oral suspension forms offer yet another example of our commitment to growing and diversifying our generics portfolio.”